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ABSTRACT
A 54-year-old male presented with visual loss owing to a giant, infiltrative pituitary adenoma. Following decompressive
trans-sphenoidal surgery, the patient was referred for adjuvant radiotherapy. We describe the potential utility of 11carbon
methionine positron emission tomography imaging in confirming the true extent of tumour infiltration, which included
the cavernous sinuses and the bones of the skull base. The co-registration of positron emission tomography imaging to
planning MR and CT imaging provided assurance of complete radiotherapy coverage of the target volume and assisted
with theminimisation of collateral radiation dose to adjacent organs at risk.
Giant pituitary adenomas (GPAs) are defined as pituitary
tumours ‡ 4 cm in maximum diameter. Although typically
benign, they can present specific challenges for disease
control.1 While neurosurgery remains the primary treat-
ment modality (particularly when vision is compromised
or threatened), a significant proportion of patients receive
adjuvant radiotherapy-reflecting the difficulty in achieving
gross total resection.2,3 Here, we describe a case in which
11carbon methionine positron emission tomography (PET)
imaging was used in radiotherapy treatment planning to
confirm the true extent of residual tumour following sur-
gery, in a patient who was found to have a giant, infiltrative
gonadotroph adenoma.
CLINICAL PRESENTATION
A 54-year-old male presented with recent onset of worsen-
ing vision that had led him to stop driving. He had a his-
tory of left-sided amblyopia secondary to a congenital
cataract and had suffered a left retinal detachment
at the age of 37 years. He was otherwise well and was on no
regular medication. Ophthalmic examination revealed a
right temporal field defect to confrontation but with pre-
served visual acuity. He could only detect hand movements
with the left eye. Physical examination was otherwise
unremarkable and there were no clinical stigmata of
endocrine dysfunction.
INVESTIGATION/IMAGING FINDINGS
An MRI scan of the pituitary demonstrated a large sellar
mass (7 cm in maximum diameter), compressing the optic
chiasm superiorly and extending inferiorly to the sphenoid
sinus (Figures 1a,b). Additionally, a CT scan confirmed
erosion of the skull base (Figure 1c). Endocrine profiling
revealed mild hyperprolactinaemia, consistent with pitui-
tary stalk disconnection syndrome [serum prolactin
430mU l–1; reference range (RR) 45–375] and a raised
serum follicle stimulating hormone (FSH) [63 U l–1; (RR
1.0–10.1)]. The remaining pituitary function tests were
unremarkable. Ultrasound scanning of the testes excluded
macro-orchidism.
TREATMENT
The patient underwent endoscopic, endonasal trans-
sphenoidal hypophysectomy. Safe and effective debulking
of the optic chiasm was achieved, with immediate improve-
ment in vision in his right eye following surgery. Histologi-
cal and immunohistochemical examinations confirmed a
pituitary adenoma with a low proliferation index (MIB-1
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staining of Ki-67 at 1.3%), patchy positivity for FSH and scat-
tered staining for luteinizing hormone (LH), consistent with a
locally infiltrative, gonadotroph adenoma. Immunohistochemi-
cal staining was negative for prolactin.
At 4 months post-operatively, vision in the right eye had
returned to normal (visual acuity 6/6, with full resolution of the
previous temporal field defect). As anticipated, a repeat
MRI scan showed substantial residual tumour, including encase-
ment of the carotid arteries (Figures 2a,b). However, the optic
chiasm had been completely decompressed. The patient initially
elected for surveillance follow-up, but a further MRI at 9 months
post-operatively showed replacement of a cystic, suprasellar
component with more solid, enhancing tumour. Additionally,
serum FSH remained elevated at 29.6 U l–1 (RR 1.0–10.1).
Following discussion of the treatment options, including further
debulking surgery, the decision was made to proceed
with radiotherapy.
To perform radiotherapy planning imaging, the patient’s head
was immobilized in a thermoplastic shell. A standard planning
MRI was obtained, namely a volumetric T1 weighted sequence
with gadolinium contrast, for co-registration to the primary CT
scan dataset. Owing to the known bony involvement, a high-
resolution bone window CT scan was also performed, and the
internal trabecular pattern of the skull was examined to assess
the limit of tumour extent. In addition to these scans, a 11carbon
methionine PET-CT scan was acquired to assist with radiother-
apy planning. The patient received an intravenous bolus of
407MBq of L-[methyl-11carbon]-methionine tracer and imaging
was performed with a Discovery 690 PET–CT scanner (General
Electric Medical Systems, Milwaukee, WI, USA) 20 min follow-
ing injection. The images confirmed the unusually widespread
extent of the residual tumour in the craniocaudal dimension and
bony involvement, including inferior invasion into the clivus,
pterygoid processes of the sphenoid, basiocciput and right occip-
ital condyle (Figure 3a,b). PET uptake in the bones of the skull
base indicated unexpectedly extensive bony infiltration, which,
once identified, was confirmed on close and detailed inspection
of the bone window CT (Figure 4a,b). While the bulk of the
tumour was generally well seen with the combination of MRI
and CT, there were areas of uncertainty regarding the true extent
of the tumour, which were resolved by the PET imaging. Specific
Figure 1. (a) Preoperative T1 weighted sagittal and (b) coronal MRI scan with contrast, and (c) CT with contrast demonstrated the
large pituitary tumour with suprasellar extension, inferior invasion and destruction of the skull base.
Figure 2. (a) Postoperative T1 weighted sagittal and (b) coronal MRI scan with contrast demonstrated extensive residual disease at
4months following decompression surgery. Maximum tumour dimensions were 61, 50 and 34mm in the craniocaudal, transverse,
and anteroposterior planes, respectively.
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extension of the radiotherapy planning margins to account for
areas of uncertainty was not necessitated, thereby minimising
the normal tissues included in the target volume. A variable clin-
ical target volume margin of 0.2–0.5 cm was used to reflect the
clarity of distinction between the tumour and adjacent struc-
tures. Owing to the non-spherical shape of the target, a planning
target volume (PTV) margin of 0.5 cm was used, which is larger
than our standard PTV margin of 0.3 cm for radiotherapy
treatment of pituitary adenomas with daily image guidance.
Treatment was delivered with rotational intensity-modulated
radiotherapy using TomoTherapy, with additional daily image
guidance and positional correction.4
The planning objective for the radiotherapy PTV was 50Gy in
30 fractions to be delivered over 6 weeks (Figure 5). This is a
slightly higher dose than is usual in our centre but clinically
Figure 3. Tumour localisation (indicated by the red box) observed on T1 weighted axial MRI (a) was confirmed on axial
11carbon
methionine PET-CT scan (b). Note the normal PET tracer uptake in the parotid glands, seen posterior and lateral to the rami of the
mandible, in the posterior wall of the nasopharynx and in themucosa of the hard palate.
Figure 4. (a) Bony invasion of tumour (indicated by the red box), as evidenced by disrupted trabecular meshwork pattern observed
on bone window CT scan, and (b) confirmed on axial 11carbon methionine PET-CT scan. Normal PET tracer uptake is seen in the
parotid glands, posterior wall of the nasopharynx and the mucosa of the hard palate. Bone marrow uptake in uninvolved bone was
not marked.
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indicated owing to the size of the residual tumour.5 Absolute
dose constraints of 50Gy were set to the planning organ at risk
volumes (PRVs) of the brain stem, optic chiasm and optic nerves
in order to prevent dose excess. An objective dose for the lenses
was set at 4Gy with an absolute dose constraint at 6Gy. The left
lacrimal gland had an objective dose of 20Gy with an absolute
constraint of 40Gy, and the right lacrimal gland an objective of
15Gy with an absolute constraint of 30Gy.
Thermoluminescent dosimetry measurements confirmed a pre-
dicted total dose to the right lens of 4.23Gy and the left lens of
4.03Gy. Mean doses to the left and right lacrimal glands were
20.9 and 14.5 Gy, respectively. For the left and right parotid
glands mean doses were 17.9 and 18.5Gy, respectively, which
should be low enough to avoid significant loss of salivary func-
tion.6 Image-guided intensity-modulated radiotherapy4 was
completed 16 months following neurosurgical resection.
OUTCOME AND FOLLOW-UP
Follow-up is relatively short at present. During radiotherapy the
patient reported more acute side effects than are typical for a
pituitary adenoma, likely owing to the large tumour volume.
Symptoms included sore throat, dry mouth, tinnitus, anorexia
and fatigue. The nasopharynx and posterior wall of the orophar-
ynx were included in the PTV. This explains his sore throat,
which was treated effectively with parcetamol. His dry mouth
resulted from radiation dose received by the parotid glands. His
tinnitus may have been related to the dose to the cochleae
(average dose of 47Gy to both). Additionally, although both
Eustacian tubes were entirely enclosed within the PTV, he did
not complain of symptoms suggestive of secretory otitis media.
His fatigue may have been related to brainstem dose.7 His FSH
level, still elevated at 33.8 U l–1 immediately prior to radiother-
apy, had reduced slightly to 28.3 U l–1 at 6 months after comple-
tion of radiotherapy. He currently requires no hormone
replacement therapy. The most recent MRI (performed at
21 months post-operatively and 5 months following radiother-
apy completion) showed stable disease.
DISCUSSION
Gonadotroph adenomas constitute 15–40% of pituitary
tumours.8 Although staining for FSH and/or LH can be clearly
demonstrated on immunohistochemistry, the majority are clini-
cally non-functioning and may go undiagnosed until they pro-
duce symptoms related to mass effect on adjacent structures. As
such, they can grow quite insidiously with invasion of the cav-
ernous sinus and skull base.9 Visual deterioration (visual field
loss and in more severe cases reduced visual acuity) secondary
to compression of the optic chiasm is the most common pre-
senting symptom. In a small number of cases, biologically active
FSH (± LH) is secreted, resulting in ovarian hyperstimulation
syndrome in females and macro-orchidism in males.10 In our
patient, serum FSH levels were markedly raised, but there was
no clinical or radiological evidence of testicular enlargement.
A pituitary adenoma with maximum diameter of at least 4 cm is
subcategorized as a GPA. Neurosurgical intervention is integral
to the treatment of GPAs, including the management of
tumour-induced visual, endocrine and neurological symptoms.1
However, owing to the invasive nature of these tumours, most, if
not all (50–100%), patients will have residual disease post-opera-
tively.1,2 While a “watch and wait” approach to radiotherapy
may be adopted to minimize and delay treatment-induced side
effects, adjuvant radiotherapy reduces the likelihood of tumour
progression and abnormal hormone secretion in those with sig-
nificant residual disease.3
Standard radiotherapy treatment planning involves the co-regis-
tration of MRI, which allows for the appreciation of tumour, to
the primary CT data set.5 In the case presented here, owing to
the large extent of the GPA, its close proximity to several
Figure 5. Axial CT scan showing intensity-modulated radiotherapy dose plan. The radiotherapy dose was 50Gy in 30 fractions over
6weeks. intensity-modulated radiotherapy was delivered with helical TomoTherapy, using daily image guidance and positional cor-
rection.4 The planning target volume is shown in red. In (a) the lenses, lacrimal glands, optic nerves and chiasm and brain stem are
contoured; in (b) contours for the parotid glands and brain stem are shown. Planning organ at risk volumes for the optic structures
and brain stemwere created, but are not shown.
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planning organ at risk volumes and the need to administer a
larger than normal dose of radiotherapy, the acquisition of addi-
tional imaging was judged necessary to appropriately contour
the tumour bed. We elected to perform a high-resolution CT
scan to detect bony infiltration and a 11carbon methionine PET-
CT scan to confirm the extent of residual tumour as suspected
on both MRI and CT scans. 11Carbon methionine PET-CT is a
potentially useful adjunct for the imaging of pituitary adenomas,
especially when conventional imaging (MRI, CT) is unable to
reliably identify the site of primary or recurrent disease or distin-
guish the latter from post-surgical change.11,12 A precursor to
protein and polyamine synthesis, methionine is key to cell
growth, proliferation and survival. In the central nervous system,
11carbon methionine tracer displays preferential uptake by the
pituitary gland. Therefore, radiolabelled methionine can be used
to distinguish pituitary adenoma tissue from surrounding struc-
tures, including normal brain.11 Distinctions between tumour
and fibrosis, blood collections and/or cysts can also be made.12
Many workers have reported its superiority in terms of pituitary
imaging compared with the more commonly used tracer
FDG13,14 and we selected it as the functional imaging modality
of choice, on this basis. In addition, methionine PET has been
specifically shown to be superior to fludeoxyglucose PET when
imaging skull base tumours.15 The PET-CT was particularly
helpful in emphasizing widespread infiltration of the GPA, dis-
tinguishing between tumour and postoperative scarring, and
providing reassurance about the tumour limits. In this way, the
PET contributed to minimising the volume of normal tissue
receiving radiotherapy.
However, the technique has some limitations: physiological
11carbon methionine uptake at sites such as lacrimal glands,
parotid glands, nasopharynx, bone marrow and normal pituitary
gland needs to be considered. This is relevant in our case, as
there was suspected bone infiltration by the tumour and PET
signal could therefore have represented methionine uptake
either in the bone marrow or pituitary tumour. We carefully
reviewed bone window CT, MRI and PET images, which were
co-registered in the radiotherapy contouring system, in order to
differentiate between normal tissues and tumour. Another
important limitation of 11carbon methionine is its short half-life
(20 min), which translates to a need to use the tracer very soon
after production, thus limiting its availability to centres that
have a cyclotron on-site.
We report a case of a giant gonadotroph adenoma presenting
with compression of the optic chiasm and associated with visual
loss. Although initial surgical debulking restored the patient’s
vision to his premorbid state, significant residual tumour
remained. 11Carbon methionine PET-CT provided independent
corroboration of the extent of the residual tumour, particularly
in relation to skull base invasion. It informed radiotherapy plan-
ning by helping to ensure complete inclusion of the target vol-
ume while concurrently minimising radiation dose to
surrounding normal tissues including the parotid glands, lacri-
mal glands and inner ears.
LEARNING POINTS
1. Although benign, giant pituitary adenomas (‡ 4 cm in
maximum diameter) may be associated with significant
morbidity. Superior extension with compression of the
optic chiasm predisposes patients to visual compromise
(Figure 1).
2. As in our case, inferolateral extension with invasion of
bony structures such as the skull base renders complete
surgical resection difficult. Many patients will have
residual disease post-operatively (Figure 2).
3. Adjuvant radiotherapy is often given to GPAs to reduce
the likelihood of disease progression. Although MRI and
CT provide complementary information to facilitate
accurate radiotherapy planning, particular challenges
exist in cases with extensive tumour invasion or where
there is postoperative scar tissue (Figure 5).
4. 11Carbon methionine PET-CT provides additional
information to help define tumour extent, delineate
radiotherapy planning margins and more reliably
distinguish post-surgical change from residual tumour.
Such confirmation ensures adequate coverage of the
target volume while concurrently minimising radiation
dose to organs at risk (Figures 3 and 4).
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